EA
ACHN

Emerald Acquisition’s Achillion Pharmaceuticals ACHN Stock Holding History

Emerald Acquisition’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.1M Sell
135,819
-42,685
-24% -$363K ﹤0.01% 2078
2016
Q2 		$1.39M Buy
+178,504
New +$1.53M ﹤0.01% 1998

Other funds holding ACHN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Emerald Acquisition's ACHN Position: Q3 2016 in Review

Emerald Acquisition reduced its Achillion Pharmaceuticals (ACHN) stake by 24% in Q3 2016, selling an estimated $363K and leaving 135,819 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2078.

Emerald Acquisition first reported a position in ACHN in Q2 2016 and has held it in 2 quarters since. The position peaked at $1.39M in Q2 2016. 162 funds tracked by Wall St. Rank hold ACHN as of Q3 2016.

  • Emerald Acquisition held 135,819 shares of Achillion Pharmaceuticals worth $1.1M as of Q3 2016.
  • Emerald Acquisition sold 42,685 Achillion Pharmaceuticals shares in Q3 2016, an estimated $363K.
  • Achillion Pharmaceuticals made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2078 holding.
  • Emerald Acquisition first reported a position in Achillion Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Achillion Pharmaceuticals position peaked at $1.39M in Q2 2016.
  • 162 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.